Advanced molecular imaging in large-vessel vasculitis: Adopting FDG-PET into a clinical workflow

Jennette, 2013, 2012 Revised international chapel hill consensus conference nomenclature of vasculitides, Arthritis Rheum, 65, 1, 10.1002/art.37715 Quinn, 2022, Use of 18F-fluorodeoxyglucose positron emission tomography to standardize clinical trial recruitment in Takayasu's arteritis, Rheumatology (Oxford), 61, 4047, 10.1093/rheumatology/keac021 Maksimowicz-McKinnon, 2007, Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients, Arthritis Rheum, 56, 1000, 10.1002/art.22404 Kerr, 1994, Takayasu arteritis, Ann Intern Med, 120, 919, 10.7326/0003-4819-120-11-199406010-00004 Expert Panel on Vascular, 2021, ACR appropriateness Criteria(R) noncerebral vasculitis, J Am Coll Radiol, 18, S380 Maz, 2021, 2021 American College of rheumatology/vasculitis foundation guideline for the management of giant cell arteritis and Takayasu arteritis, Arthritis Rheumatol, 73, 1349, 10.1002/art.41774 Dejaco, 2018, EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice, Ann Rheum Dis, 77, 636, 10.1136/annrheumdis-2017-212649 Wahl, 2021, At last, (18)F-FDG for inflammation and infection, J Nucl Med, 62, 1048, 10.2967/jnumed.121.262446 Ponte, 2022, 2022 American College of rheumatology/EULAR classification Criteria for giant cell arteritis, Arthritis Rheumatol, 74, 1881, 10.1002/art.42325 Grayson, 2022, 2022 American College of rheumatology/EULAR classification Criteria for Takayasu arteritis, Arthritis Rheumatol, 74, 1872, 10.1002/art.42324 Gribbons, 2020, Patterns of arterial disease in Takayasu arteritis and giant cell arteritis, Arthritis Care Res, 72, 1615, 10.1002/acr.24055 Lee, 2016, Diagnostic accuracy of 18F-FDG PET or PET/CT for large vessel vasculitis : a meta-analysis, Z Rheumatol, 75, 924 Nielsen, 2018, Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy, Eur J Nucl Med Mol Imag, 45, 1119, 10.1007/s00259-018-4021-4 Betrains, 2023, Higher diagnostic yield of 18F-FDG PET in inflammation of unknown origin compared to fever of unknown origin, Eur J Intern Med, 110, 71, 10.1016/j.ejim.2023.01.025 Schonau, 2018, The value of (18)F-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO): data from a prospective study, Ann Rheum Dis, 77, 70, 10.1136/annrheumdis-2017-211687 Chen, 2009, Emerging role of FDG-PET/CT in assessing atherosclerosis in large arteries, Eur J Nucl Med Mol Imag, 36, 144, 10.1007/s00259-008-0947-2 Quinn, 2020, Patterns of clinical presentation in Takayasu's arteritis, Semin Arthritis Rheum, 50, 576, 10.1016/j.semarthrit.2020.04.012 Parodis, 2019, G-CSF-induced aortitis: two cases and review of the literature, Autoimmun Rev, 18, 615, 10.1016/j.autrev.2018.12.011 Boland, 2020, Immune checkpoint inhibitors and vasculitis, Curr Opin Rheumatol, 32, 53, 10.1097/BOR.0000000000000672 Grayson, 2018, F-Fluorodeoxyglucose-Positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis, Arthritis Rheumatol, 70, 439, 10.1002/art.40379 Ostberg, 1972, Morphological changes in the large arteries in polymyalgia arteritica, Acta Med Scand Suppl, 533, 135, 10.1111/j.0954-6820.1972.tb15615.x Quinn, 2023, Association of (18) F-Fluorodeoxyglucose-Positron emission tomography activity with angiographic progression of disease in large vessel vasculitis, Arthritis Rheumatol, 75, 98, 10.1002/art.42290 Tahra, 2022, Assessment of Takayasu arteritis in routine practice with PETVAS, an 18F-FDG PET quantitative scoring tool, Turk J Med Sci, 52, 313, 10.55730/1300-0144.5317 Galli, 2022, The role of PET/CT in disease activity assessment in patients with large vessel vasculitis, Rheumatology (Oxford), 61, 4809, 10.1093/rheumatology/keac125 Kang, 2020, Performance of the PET vascular activity score (PETVAS) for qualitative and quantitative assessment of inflammatory activity in Takayasu's arteritis patients, Eur J Nucl Med Mol Imag, 47, 3107, 10.1007/s00259-020-04871-2 Schonau, 2021, Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study, Rheumatology (Oxford), 60, 3851, 10.1093/rheumatology/keab332 Park, 2018, Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study, Rheumatol Int, 38, 2233, 10.1007/s00296-018-4159-1 Quinn, 2021, Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis, Rheumatology (Oxford), 60, 4384, 10.1093/rheumatology/keaa894 Blockmans, 2006, Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients, Arthritis Rheum, 55, 131, 10.1002/art.21699 Sammel, 2020, Cranial and large vessel activity on positron emission tomography scan at diagnosis and 6 months in giant cell arteritis, Int J Rheum Dis, 23, 582, 10.1111/1756-185X.13805 Janes, 2020, A retrospective cohort study to assess PET-CT findings and clinical outcomes in Takayasu arteritis: does 18F-fluorodeoxyglucose uptake in arteries predict relapses?, Rheumatol Int, 40, 1123, 10.1007/s00296-020-04551-2 Ma, 2023, PET vascular activity score for predicting new angiographic lesions in patients with Takayasu arteritis: a Chinese cohort study, Rheumatology (Oxford), 10.1093/rheumatology/kead056 Pugh, 2022, Large-vessel vasculitis, Nat Rev Dis Prim, 7, 93, 10.1038/s41572-021-00327-5 van der Geest, 2022, Novel PET imaging of inflammatory targets and cells for the diagnosis and monitoring of giant cell arteritis and polymyalgia rheumatica, Front Med (Lausanne)., 9 Corovic, 2023, Somatostatin receptor PET/MR imaging of inflammation in patients with large vessel vasculitis and atherosclerosis, J Am Coll Cardiol, 81, 336, 10.1016/j.jacc.2022.10.034 Slart, 2018, FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC, Eur J Nucl Med Mol Imag, 45, 1250, 10.1007/s00259-018-3973-8 Campochiaro, 2022, PET in Takayasu arteritis: onwards and upwards towards a future of robust multimodality disease activity assessment?, Rheumatology (Oxford), 61, SI4, 10.1093/rheumatology/keab644 Narvaez, 2023, Efficacy and safety of leflunomide in the management of large vessel vasculitis: a systematic review and metaanalysis of cohort studies, Semin Arthritis Rheum, 59, 10.1016/j.semarthrit.2023.152166 Marinelli, 2019, Stenosis and pseudostenosis of the upper extremity arteries in large-vessel vasculitis, ACR Open Rheumatol, 1, 156, 10.1002/acr2.1018 Quinn, 2020, Imaging acquisition technique influences interpretation of positron emission tomography vascular activity in large-vessel vasculitis, Semin Arthritis Rheum, 50, 71, 10.1016/j.semarthrit.2019.07.008 Lodge, 2012, Noise considerations for PET quantification using maximum and peak standardized uptake value, J Nucl Med, 53, 1041, 10.2967/jnumed.111.101733 Ora, 2023, Metabolic inflammatory volume and total inflammatory glycolysis: novel parameters to evaluate PET-CT disease activity in Takayasu arteritis, Clin Rheumatol, 42, 1855, 10.1007/s10067-023-06600-0 Dashora, 2022, Comparing semiquantitative and qualitative methods of vascular (18)F-FDG PET activity measurement in large-vessel vasculitis, J Nucl Med, 63, 280, 10.2967/jnumed.121.262326 Cheson, 2014, Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, J Clin Oncol, 32, 3059, 10.1200/JCO.2013.54.8800